Chinese biotech picks Durham for $157 million, 200-job operation - (Triangle Business Journal via NewsPoints Desk)

  • CARsgen Therapeutics has selected Durham County, North Carolina for a $157 million expansion of its R&D and commercial manufacturing operation, Triangle Business Journal reported.

  • The company, which has clinical development operations in Houston, said it expects to invest $157 million in the operation by 2025.

  • The project is expected to create 200 new jobs between 2022 and 2026.

  • "CARsgen will continuously develop and embed innovations to advance the revolutionary CAR-T cell therapy for unmet clinical needs," said CEO Zonghai Li.

  • "The company has launched clinical studies of our leading CT053 and CT041 CAR-T cell therapies in the US," Li said, adding that "The new facilities will expand our global cGMP manufacturing capacity to produce the innovative CAR-T cell products for the US patients."

To read more NewsPoints articles, click here.

Reference Articles